In obese, insulin-resistant C57BL/6J mice Xu and colleagues reported that empagliflozin diminished weight gain and reduced deteriorations of insulin sensitivity and hepatic steatosis of ongoing high-fat-diet feeding [12, 24]. This evidence concerns the gene INS and fatty liver disease.